Loss of power etc. [Design Issues]

posted by Astea – Russia, 2016-03-29 01:57 (3743 d 04:19 ago) – Posting: # 16150
Views: 27,225

Dear all!

I understand clear that post-hoc power is set yours teeth on edge, but I'll take a chance to ask a question once more... There was a study with one drop-out. The results of that subject have not been included in the calculation. Recently the customers received a reply from regulatories to calculate aposteriory power and in the case of insufficient power present a plan for further clinical development of the drug.

I estimated power with the help of power.TOST, based on obtained GMR and CV. The result is: power is less than 80% for AUC and more than 80% for Cmax. I remade the calculation including the drop-out: power for AUC is still less than 80%!

Funny thing, but the drugs were bioequivalent! Moreover they are bioequivalent nevetherless including drop-out's results or not! And that fact was already stated in the report. What to do in such a situation? :confused:

"Being in minority, even a minority of one, did not make you mad"

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
386 visitors (0 registered, 386 guests [including 28 identified bots]).
Forum time: 06:17 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5